BMT-13

A Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Myeloablative Fludarabine/Busulfan and Post-Transplant Cyclophosphamide (PTCY) for Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients with High-Risk AML, CML, and MDS

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
38 patients (estimated)
Sponsors
University of Illinois at Chicago
Tags
Pre-Allogeneic Stem Cell Transplant, Radiation Therapy
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
2057
NCT Identifier
NCT06802315

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.